History
A list of downloadable documents created during development.
Review proposal consultation
Background information
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - guidance review - May 2013
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - guidance review - May 2013
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination document
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): consultee and commentator comments on the ACD
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Roche Products
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome (PDF 101 KB)
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Target Ovarian Cancer
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Nursing
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Pathologists
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Physicians (NCRI Gynaecological Cancer Clinical Studies Group/RCP/RCR/ACP/JCCO)
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Department of Health
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NHS outer north east London cluster
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Commissioning Support Appraisals Service
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Southampton Health Technology Assessments Centre
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): comments on the ACD received from the public through the NICE website
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appraisal consultation
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appraisal consultation
-
-
-
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appeal
-
-
Appeals received
-
-
Initial scrutiny letter - Pharma Mar
-
-
Response to scrutiny letter
-
-
Final scrutiny letter
-
-
-
-
-
-
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: final appraisal determination document
-
-
-
-
-
-
Ovarian Cancer Topotecan Pegylated Liposomal Doxorubicin Hydrochloride Paclitaxel Trabectedin and Gemcitabine (Review) Assessment Report - Consultation
-
-
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final protocol
-
-
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final scope (post CIM)
-
-
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final matrix
-
-
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): NICE response to consultee and commentator comments on the draft scope
-
-
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): equality impact assessment form - scoping
-
-
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft scope
-
-
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft matrix
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): evaluation report
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Pre-meeting briefing
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Evidence Review Group report
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Evidence Review Group report - factual accuracy check
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Manufacturer submission - Roche
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Clarification
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NICE clarification letter
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Manufacturer response to the NICE clarification letter
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Patient group, professional group and NHS organisation submission statements
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NCRI Gynaecological CSG/RCP/RCR/ACP/JCCO
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome (PDF 107 KB)
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovarian Cancer Action
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Nursing
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Pathologists
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Target Ovarian Cancer
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Expert written personal statements
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Marcia Hall
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Sharon Tate
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Sarah Blagden
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Louise Bayne
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Rajinder Nijjar
-
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Oge Chesa
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the provisional matrix - July 2012
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the provisional matrix - July 2012
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the draft remit and draft scope - June 2012
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the draft remit and draft scope - June 2012
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope - June 2012
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope - June 2012
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix - July 2012
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix - July 2012
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - scoping - June 2012
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - scoping - June 2012
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope (PDF 47 KB)
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft matrix
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft matrix
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft scope
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft scope
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix B - draft scope for consultation (pre-referral) August 2010
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix B - draft scope for consultation (pre-referral) August 2010
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix C - provisional matrix (pre-referral) August 2010
-
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix C - provisional matrix (pre-referral) August 2010
-